191 related articles for article (PubMed ID: 36333070)
1. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract][Full Text] [Related]
2. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
3. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
5. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract][Full Text] [Related]
6. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract][Full Text] [Related]
7. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.
Pardanani A; Lasho TL; Finke CM; Mai M; McClure RF; Tefferi A
Leukemia; 2010 Jun; 24(6):1146-51. PubMed ID: 20410924
[TBL] [Abstract][Full Text] [Related]
8. Management of advanced phase myeloproliferative neoplasms.
Marcellino B; Mascarenhas J
Clin Adv Hematol Oncol; 2019 Jul; 17(7):405-411. PubMed ID: 31449507
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract][Full Text] [Related]
10. Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges.
Ajufo HO; Waksal JA; Mascarenhas JO; Rampal RK
Ther Adv Hematol; 2023; 14():20406207231177282. PubMed ID: 37564898
[TBL] [Abstract][Full Text] [Related]
11. Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.
Bartels S; Vogtmann J; Schipper E; Büsche G; Schlue J; Lehmann U; Kreipe H
Eur J Haematol; 2021 Apr; 106(4):520-528. PubMed ID: 33460496
[TBL] [Abstract][Full Text] [Related]
12. A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.
Chen D; Fuda F; Weinberg O
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():78-81. PubMed ID: 34288445
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
Khan M; Siddiqi R; Gangat N
Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Badar T; Kantarjian HM; Ravandi F; Jabbour E; Borthakur G; Cortes JE; Pemmaraju N; Pierce SR; Newberry KJ; Daver N; Verstovsek S
Leuk Res; 2015 Sep; 39(9):950-6. PubMed ID: 26183878
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Cherington C; Slack JL; Leis J; Adams RH; Reeder CB; Mikhael JR; Camoriano J; Noel P; Fauble V; Betcher J; Higgins MS; Gillette-Kent G; Tremblay LD; Peterson ME; Olsen JJ; Tibes R; Mesa RA
Leuk Res; 2012 Sep; 36(9):1147-51. PubMed ID: 22578777
[TBL] [Abstract][Full Text] [Related]
17. Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.
Yogarajah M; Tefferi A
Mayo Clin Proc; 2017 Jul; 92(7):1118-1128. PubMed ID: 28688466
[TBL] [Abstract][Full Text] [Related]
18. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
Rampal RK; Mascarenhas JO; Kosiorek HE; Price L; Berenzon D; Hexner E; Abboud CN; Kremyanskaya M; Weinberg RS; Salama ME; Menghrajani K; Najfeld V; Sandy L; Heaney ML; Levine RL; Mesa RA; Dueck AC; Goldberg JD; Hoffman R
Blood Adv; 2018 Dec; 2(24):3572-3580. PubMed ID: 30563881
[TBL] [Abstract][Full Text] [Related]
20. MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
He Z; Wang B; Chen L; Huang Y; Wang H; Yang M; Xiao X; Lu Y; Chen J; Wu Y
Medicine (Baltimore); 2018 Nov; 97(46):e13220. PubMed ID: 30431598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]